Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF, a New Plateau -- Ignore unavailable to you. Want to Upgrade?

To: WhatsUpWithThat who wrote (718)	11/6/2001 10:18:13 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 2243

Don't follow them closely, sorry. If you're willing to tell us how an immunogenic virus can be effective upon repeat administration and at distant sites to administration, then you're welcome to describe the company and its efforts here. Otherwise, I'll just go on assuming that any local regressions will have no overall patient benefit, that a large phase II or phase III trial will show that reolysin lends no survival benefit. What was the close for ONXX on 7/31/00, what has happened since. and why won't it happen to Oncolytics?............. Message 14140190 I have no bias, apart from that of an immunologist who has some experience with viral serology. If you can make a strong case, great. If not, please don't comment further. Thanks.